Parkinson Toulouse Expert Centre, Toulouse University Hospital, Toulouse, France.
Department of Neurosciences, Clinical Investigation Center CIC 1436, Parkinson Toulouse Expert Center, NS-Park/FCRIN Network and NeuroToul COEN Center, Toulouse University Hospital, Toulouse, France.
Neurodegener Dis Manag. 2021 Jun;11(3):193-206. doi: 10.2217/nmt-2021-0006. Epub 2021 Mar 22.
Since 2016, opicapone (OPC), a potent third-generation, long-acting, once-daily, peripheral catechol-O-methyltransferase inhibitor, is approved as an add-on to levodopa in Parkinson's disease patients with motor fluctuations. OPC 50 mg has showed to be able in reducing OFF time by an average of about 60 min daily compared with placebo, to further reduce OFF-time of about 39 min, when switched from ENT to OPC and to be safe. These beneficial effects of OPC were maintained for 1 year. Recently, several analysis and few pilot observational open-label studies, have suggested its efficacy and wider applicability for different phenotypes of motor complications and for Parkinson's disease stages. Here we review OPC applicability and perspectives, in the light of the more recently published analysis.
自 2016 年以来，作为一种强效的第三代、长效、每日一次、外周儿茶酚-O-甲基转移酶抑制剂，opicapone（OPC）已被批准作为帕金森病运动波动患者左旋多巴的附加治疗药物。与安慰剂相比，OPC50mg 可平均减少每日约 60 分钟的停药时间，当从恩他卡朋转换为 OPC 时，可进一步减少约 39 分钟的停药时间，且安全性良好。OPC 的这些有益作用可维持 1 年。最近，几项分析和少数试点观察性开放标签研究表明，OPC 对不同运动并发症表型和帕金森病阶段具有疗效和更广泛的适用性。在此，我们根据最近发表的分析，综述了 OPC 的适用性和前景。
